Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
421 Results for "
GPCR internalization
" in MedChemExpress (MCE) Product Catalog:
Products (421)
421 Results for "GPCR internalization" in MCE Product Catalog:
266
266 Publications Verification
Synonyms: Angiotensin II; Ang II; DRVYIHPF
Target:
266
266 Publications Verification
Synonyms: Angiotensin II acetate; Ang II acetate; DRVYIHPF acetate
Target:
Research Areas:
Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology Cancer
266
266 Publications Verification
Synonyms: Angiotensin II TFA; Ang II TFA; DRVYIHPF TFA
Target:
Research Areas:
42
42 Cited Publications
Research Areas:
SBI-115 is a TGR5 (GPCR19) antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5 .
33
33 Cited Publications
Synonyms: Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium
33
33 Cited Publications
Synonyms: Ursodeoxycholate; Ursodiol; UDCA
11
11 Cited Publications
Cat. No.: HY-W008947
CAS No.: 256414-75-2
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology
SEW2871 is an orally active, potent, highly selective S1P1 (sphingosine-1-phosphate type 1 receptor) agonist, with an EC50 of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood. SEW2871 can be used for the research of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses .
11
Target:
Research Areas:
Siponimod (BAF-312) is an orally active, blood-brain barrier penetrant dual agonist of S1P1/S1P5, with EC50 values of 0.39 nM and 0.98 nM, respectively. Siponimod induces S1P1 internalization, activates GIRK channels, inhibits lymphocyte egress, reduces peripheral lymphocyte counts, triggers transient bradycardia, prevents synaptic neurodegeneration, promotes remyelination, alleviates demyelination, and prevents the loss of GABAergic interneurons. Siponimod can be used in research related to multiple sclerosis .
11
11 Cited Publications
Synonyms: BAF-312 hemifumarate
Target:
Research Areas:
Siponimod (BAF-312) hemifumarate is an orally active, blood-brain barrier penetrant dual agonist of S1P1/S1P5, with EC50 values of 0.39 nM and 0.98 nM, respectively. Siponimod hemifumarate induces S1P1 internalization, activates GIRK channels, inhibits lymphocyte egress, reduces peripheral lymphocyte counts, triggers transient bradycardia, prevents synaptic neurodegeneration, promotes remyelination, alleviates demyelination, and prevents the loss of GABAergic interneurons. Siponimod hemifumarate can be used in research related to multiple sclerosis .
9
9 Cited Publications
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .
7
7
7
Target:
6
6 Cited Publications
Target:
Research Areas:
NUCC-390 dihydrochloride is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 dihydrochloride induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046) . NUCC-390 dihydrochloride promotes nerve recovery of function after neurodegeneration in vivo .
6
6 Cited Publications
Target:
Research Areas:
NUCC-390 is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046) . NUCC-390 promotes nerve recovery of function after neurodegeneration in vivo .
6
6 Cited Publications
Cat. No.: HY-P2106
CAS No.: 1886973-05-2
Target:
Research Areas:
6
6 Cited Publications
Cat. No.: HY-P2106A
Target:
Research Areas:
4
4 Cited Publications
Cat. No.: HY-W010907
CAS No.: 6640-22-8
Research Areas:
Pamoic acid disodium is a potent GPR35 agonist with an EC50 value of 79 nM. Pamoic acid disodium induces GPR35 internalization and activates ERK1/2 with EC50 values of 22 nM and 65 nM, respectively. Pamoic acid disodium potently recruits β-arrestin2 to GPR35 and has an antinociceptive effect .
4
4 Cited Publications
Cat. No.: HY-P2336A
Target:
Research Areas:
4
4 Cited Publications
Research Areas:
VUF11207 is a potent, selective, and orally active CXCR7/ACKR3 agonist (pKi = 8.1). VUF11207 specifically activates CXCR7/ACKR3, recruits β-arrestin, and induces receptor internalization, while downregulating the pro-inflammatory, pro-osteoclastogenic, and tumor immunosuppressive signaling mediated by the CXCL12-CXCR4 axis. VUF11207 can be used for research on glioblastoma, hypertension, and venous thrombosis .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
